The cultural revolution over psychedelic drugs continues to astonish me.

Richard Nixon’s “War on Drugs,” launched in 1971, brainwashed millions of Americans into believing that psychedelic drugs were the devil’s playground. LSD, psilocybin (the psychoactive ingredient in magic mushrooms), MDMA, and similar substances were associated with unkempt hippies, bomb-throwing radicals, and Charlie Manson-type psychos.

No longer! Psychedelics are increasingly championed by lawmakers, the medical establishment, Big Pharma, and Wall Street. Corporate executives, affluent suburbanites, and other respectable members of mainstream society are avidly micro-dosing psychedelics for psychological and physical benefits.

All the while, psychedelics remain illegal in the U.S. on the federal level, which has prompted a slew of states and localities to legalize them. When the federal ban is inevitably lifted, psychedelics will blossom into a massive money-making investment opportunity.

If a new poll is any indication, that federal ban won’t last long.

A publication called Breakthrough Bulletin recently conducted a survey of 1,704 voters nationally to measure how the American public views psychedelic drugs and their increasing legalization.

The poll results, released in late March, show that most respondents are disappointed with the quality and scope of mental health treatment in America, and they view psychedelic drug treatment as a major tool in alleviating that problem.

Most respondents said they know a friend or family member who has experienced a serious mental health condition such as depression or anxiety.

The results also show strong voter support for both regulated access to psychedelic medicine and removing criminal penalties for possessing psychedelic substances.

The Top 10 Findings

Let’s review the poll’s most noteworthy results:

1. Most voters know a family member, close personal friend, or co-worker who has experienced depression (58%) or anxiety (55%).

2. Nearly half of voters reported personally experiencing symptoms of mental illness including anxiety (48%) and depression (44%).

3. Two-thirds of voters (68%) believe lawmakers in their state aren’t sufficiently focused on mental health. This view is shared across age, race, gender, and educational attainment.

4. Voters support regulated access to psychedelic therapy, and that support remains steadfast even after exposure to prohibitionist messages.

5. Most voters (60%) support changing the law to give adults access to regulated psychedelic treatment. Net support for expanded access for adults stands at +55 for Democrats; +36 for Independents; and + 18 for Republicans (see chart).

6. Support for regulated access to psychedelic medicine shoots up eight percentage points to 68% when voters are informed that evidence from leading medical institutions suggests that psychedelic medicine can be very effective in treating mental health conditions.

7. Republican support jumps from 49% without context to 67%, even among the politically conservative, when voters are informed of empirical scientific research that shows the efficacy of LSD, psilocybin, MDMA, and other psychedelic drugs to alleviate mental health disorders.

8. Opposition messaging didn’t make a dent in popular support for psychedelics. An example of this messaging, as conveyed in the poll: “These substances are known to cause people to hallucinate and enter an altered state of reality, which can be dangerous, both to the person receiving the treatment and those who administer it.”

Even after reading that statement, support for changing the law to give adults access to regulated psychedelic therapy held strong at 58%. Net support stood at +65 for Democrats; +30 for Independents; and + 5 for Republicans.

9. Most voters (58%) reported that they would be more likely to support a legislator in their upcoming election if that legislator voted to pass a law to give adults over 21 access to regulated psilocybin treatment.

10. Most voters (53%) support changing federal law to remove criminal penalties for possession of psychedelic substances. Just 29% of voters oppose changing the law to remove criminal penalties.

Read This Story: The Winding Road to Psychedelics Legalization

As an increasing number of states and localities legalize psychedelics, the stakes are getting huge for investors.

According to the Journal of the American Medical Association, there are more than 50 publicly traded companies related to the development or administration of psychedelic drugs in the U.S., with at least three valued at more than $1 billion. The U.S. market for psychedelic substances is projected to grow from $2 billion in 2020 to $10.75 billion by 2027.

In the November 2022 midterms, Colorado and Oregon voters passed initiatives in their states to decriminalize the use of psychedelics such as psilocybin. Other states are getting ready to follow suit.

Entrepreneurs, consumers and investors are jumping aboard the psychedelics movement, an accelerating trend that’s reminiscent of the legal and societal normalization of marijuana.

We’re now on the cusp of a “breakout” year for marijuana and the ancillary industry of psychedelics. That’s why I’ve launched an investment service called Marijuana Profit Alert.

My publication provides specific, actionable advice on the best investments in the psychotropic megatrend. In my portfolio of holdings, I strive to strike the right balance between risk and reward. Click here to learn more.

John Persinos is the editorial director of Investing Daily.

To subscribe to John’s video channel, click this icon: